Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atorvastatin/aspirin/metoprolol/ramipril - Zydus Cadila

Next Previous
Drug Profile

Atorvastatin/aspirin/metoprolol/ramipril - Zydus Cadila

Latest Information Update: 21 Mar 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cadila Healthcare; Zydus Cadila
  • Developer Zydus Cadila; Zydus Lifesciences
  • Class Antihyperlipidaemics; Antihypertensives; Antiplatelets; Class II antiarrhythmics; Fatty acids; Heptanoic acids; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Propanolamines; Pyrroles; Salicylates; Small molecules
  • Mechanism of Action ACE inhibitors; Beta 1 adrenergic receptor antagonists; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Ischaemic heart disorders

Most Recent Events

  • 07 Aug 2015 No recent reports on development identified - Phase-III for Ischaemic heart disorders in India (PO)
  • 26 Mar 2010 Cadila Healthcare and Zydus Cadila complete a phase III trial in Ischaemic heart disorders in India

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top